Table 2 Gene expression profile signatures of Myc protein overexpression in DLBCL, GCB-DLBCL, and ABC-DLBCL

From: Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

 

DLBCL

GCB-DLBCL

ABC-DLBCL

 

Myc high vs Myc low (false discovery rate <0.05, fold change >1.53)

Myc high vs Myc low (false discovery rate <0.01, fold change >1.68)

Myc high vs Myc low (false discovery rate <0.01, fold change >1.31)

Upregulated

MYC, AICDA, SNHG1, SNHG4, TMEM97, PAICS, TCL1A, XK, FAM129C, CKS2, PEG10, IGF2BP3, SLC16A1, FAM72A/B/C/D, HELLS, CDCA7L, MAD2L1, MRPL3, PRO2964, C13orf18, MIR17HG

MYC, PEG10, SNHG4, STRBP, CYP39A1, DKFZp686O24166, PAICS, FAM72A/B/C/D, CDC25A, SLC16A1, RPS21, DEPDC1, HSPD1

MYC, MAD2L1, EEF1E1, RUVBL2, SNHG1, RG9MTD1, MRPL3, IPO7, CCDC86, TFAM, GAR1, MATR3, SNHG4, TOMM5, NOC3L, WDR43, DDX21, LYAR, RPL24, LOC388796, SNHG8, WDR75, DCTPP1, MAT2A, QDPR, APEX1

Downregulated

CD3E, HOPX, TRBC1, COL3A1, RGS1, COL3A1, TRBC1, ITM2A, GZMK, ITGB5, ITM2A

MIR155HG, TRBC1, GABBR1/UBD, CD58, CD3E, BHLHE41, GZMK, DUSP4, TRBC1, SLAMF7, LCP2, RGS1, ITM2A, SKI, SLAMF8, CD44, LOC285628, FYB, CCL5, MDFIC, CCND2, BCL11B, TNFAIP3, SLFN5, SNX9, IL10RA, GBP2

 
  1. Abbreviations: ABC, activated B-cell-like; DLBCL, diffuse large B-cell lymphoma; GCB, germinal center B-cell-like; Mychigh, high Myc protein expression; Myclow, low Myc protein expression.
  2. Note: Genes are listed by the order of fold change (high to low).
Back to article page